• Lexaria Bioscience reached 70 patent awards with four new grants covering its DehydraTECH drug-delivery technology in the US, Canada and Europe.
• A US patent granted July 28, 2026, covers DehydraTECH processes for GLP-1 drugs to treat diabetes.
• A second US patent, granted October 13, 2026, covers DehydraTECH-processed cannabidiol for diabetes treatment.
• Canadian patent protection for DehydraTECH-processed cannabidiol to treat hypertension was granted October 20, 2026.
• European patent protection for DehydraTECH-processed cannabidiol to treat epilepsy carries an October 21, 2026, grant date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.